I don't know if it is age, experience, or both (probably both), where investors here do not understand the dynamics of this business. When you are an upstart, with great potential with a potential class leading drug, like Ariad was, Mr. Market will allow you an enormous market cap, approaching $4 billion. If you stumble, and your drug is only for third-fourth line patients who will only need it for 6-9 months, to coin a phrase, it is "game over" for the company to remain independent. It is simply impossible to fund the business with that resultant cash flow. That is why there is hardly any coverage or recommendations from Wallstreet for Ariad. They know somethin' is happening here, what it is isn't exactly clear...
Again, the next Biggest, Stupid, move by Ariad was trying to "force fit" one dose for '113. When the history is written, that will be noted as to why they lost the company..
